IDEXX Laboratories (NASDAQ: IDXX) is one of 256 public companies in the “MED PRODS” industry, but how does it compare to its rivals? We will compare IDEXX Laboratories to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.
Risk & Volatility
IDEXX Laboratories has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, IDEXX Laboratories’ rivals have a beta of 0.96, meaning that their average stock price is 4% less volatile than the S&P 500.
This table compares IDEXX Laboratories and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IDEXX Laboratories Competitors||-651.16%||-111.51%||-15.73%|
Institutional and Insider Ownership
87.1% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 52.5% of shares of all “MED PRODS” companies are owned by institutional investors. 2.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 15.4% of shares of all “MED PRODS” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for IDEXX Laboratories and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IDEXX Laboratories Competitors||1083||4502||8424||275||2.55|
IDEXX Laboratories presently has a consensus target price of $190.67, indicating a potential upside of 0.19%. As a group, “MED PRODS” companies have a potential upside of 14.72%. Given IDEXX Laboratories’ rivals higher probable upside, analysts plainly believe IDEXX Laboratories has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares IDEXX Laboratories and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IDEXX Laboratories||$1.97 billion||$263.14 million||64.73|
|IDEXX Laboratories Competitors||$3.71 billion||$128.09 million||-2.03|
IDEXX Laboratories’ rivals have higher revenue, but lower earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
IDEXX Laboratories beats its rivals on 7 of the 13 factors compared.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.